1Fine MJ,Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-aequired pneumonia. A rectaanalysis. JAMA, 1996,275 : 134-141.
2Ewig S, Ruiz M, Mensa J, et al. Severe community-acquired pneumonia. Assessment of severity criteria. Am J Respir Crit Care Med, 1998,158 : 1102-1108.
4Fry AM, Shay DK, Holman RC, et al. Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. JAMA, 2005,294 : 2712- 2719.
8Arnold FW, Summersgill JT, Lajoie AS, et al. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med,2007,175:1086-1093.
4Ngeow YF,Suwanjutha S,Chantarojanasriri T,et al.An asian study on the prevalence of atypical respiratory pathogens in community-acquired pneumonia.Int J Infect Dis,2005,9:144-153.
5Lepow ML,Balassanian N,Emmerich J,et al.Interrelationships of viral,mycoplasmal,and bacterial agents in uncomplicated pneumonia.Am Rev Respir Dis,1968,97:533-545.
6Lim WS,Macfarlane JT,Boswell TC,et al.Study of community acquired pneumonia aetiology(SCAPA) in adults admitted to hospital:implications for management guidelines.Thorax,2001,56:296-301.
7Niederman MS,Mandell LA,Anzueto A,et al.Guidelines for the management of adults with community-acquired pneumonia.Diagnosis,assessment of severity,antimicrobial therapy,and prevention.Am J Respir Crit Care Med,2001,163:1730-1754.
8Heffelfinger JD,Dowell SF,Jorgensen JH,et al.Management of community-acquired pneumonia in the era of pneumococcal resistance:a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.Arch Intern Med,2000,160:1399-1408.
9[1]Gaydos CA,Quinn TC ,Eiden JJ.Identification of Chlamydia pneumoniae by DNA amplification of the 16SrRNA gene[J]. J Clin Microbiol, 1992, 30:796-800
10[2]Ieven M,Ursi D, van Bever H, et al.Detection of Mycoplasma pneumoniae by two polymerase chain reactions and role of M.pneumoniae in acute respiratory tract infections in pediatric patients[J]. J Infect Dis,1996, 173:1445-1452